FLT3 (Ab 591) Antilichaam

FLT3 encodes a class III receptor tyrosine kinase that regulates hematopoiesis. The receptor consists of an extracellular domain composed of five immunoglobulin-like domains, one transmembrane region, and a cytoplasmic kinase domain split into two parts by a kinase-insert domain. The receptor is activated by binding of the fms-related tyrosine kinase 3 ligand to the extracellular domain, which induces homodimer formation in the plasma membrane leading to autophosphorylation of the receptor. The activated receptor kinase subsequently phosphorylates and activates multiple cytoplasmic effector molecules in pathways involved in apoptosis, proliferation, and differentiation of hematopoietic cells in bone marrow. Mutations that result in the constitutive activation of this receptor result in acute myeloid leukemia and acute lymphoblastic leukemia.

2322

P36888

NP_004110.2

Human

FLT3 (Ab-591) antibody was raised against a peptide sequence around aa.589~593 (Y-F-Y-V-D) derived from Human FLT3.

Unconjugated

Primary Antibodies

Other

Antibodies were purified by affinity-chromatography using epitope-specific peptide.

1 mg/mL

Antibody supplied in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

None

Blue Ice

Store antibody at -20˚ C for up to one year.

130, 160 kDa

This antibody detects endogenous level of total FLT3 protein.

Western Blot: 1:500~1:1000, Immunofluorescence: 1:100~1:200

FLT3

Fms-related tyrosine kinase 3

Homo sapiens

Sekine S et, al. (2008) J Immunol. ;180 (12) : 8126-34Pratz K et, al. (2008) Leuk Lymphoma. 2008 ;49 (5) : 852-63. Al Shaer L et, al. (2008) Br J Haematol. 141 (4) : 483-93.

FLK2, STK1, CD135, FLK-2, CDKN6, FLT-3, FLT3, STK-1

WB, IF

121114304

Liquid